Features of the parkinsonian syndrome induced experimentally by a deficit of nigrostriatal dopamine and stimulation of cholinergic neurons of the caudate nuclei.
Kryzhanovskii
G N
GN
Laboratory of the General Pathology of the Nervous System, Russian Academy of Medical Sciences.
Atadzhanov
M A
MA
Voronina
T A
TA
Nerobkova
L N
LN
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015655:1-Methyl-4-phenylpyridinium; D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D002421:Caudate Nucleus / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D004298:Dopamine / Q000502:physiology*; D004594:Electrophysiology; D008297:Male; D009068:Movement / Q000187:drug effects / Q000502:physiology; D017072:Neostriatum / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D010095:Oxotremorine / Q000494:pharmacology; D010275:Parasympathetic Nervous System / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000503:physiopathology*; D051381:Rats; D013378:Substantia Nigra / Q000502:physiology*
D010095:Oxotremorine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000109:Acetylcholine; D015655:1-Methyl-4-phenylpyridinium; D004298:Dopamine